This page provides comprehensive rankings of clinical trials in neurodegenerative diseases, evaluating candidates based on scientific rigor, patient impact, therapeutic potential, and likelihood of success. The rankings synthesize data from ClinicalTrials.gov, peer-reviewed literature, and expert analyses to identify the most promising therapeutic candidates across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and related disorders[@clinicaltrialsgov2024].
The neurodegenerative disease drug development landscape has evolved dramatically over the past decade, with disease-modifying therapies finally reaching regulatory approval. The 2021 approval of aducanumab marked a watershed moment for Alzheimer's research, followed by the 2023 approvals of lecanemab and donanemab, representing the first generation of amyloid-targeting therapies to demonstrate meaningful clinical benefit[@cummings2024]. This page tracks these and other promising candidates across all stages of development.
Trials are evaluated using a multi-factor assessment framework:
This page provides comprehensive rankings of clinical trials in neurodegenerative diseases, evaluating candidates based on scientific rigor, patient impact, therapeutic potential, and likelihood of success. The rankings synthesize data from ClinicalTrials.gov, peer-reviewed literature, and expert analyses to identify the most promising therapeutic candidates across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and related disorders[@clinicaltrialsgov2024].
The neurodegenerative disease drug development landscape has evolved dramatically over the past decade, with disease-modifying therapies finally reaching regulatory approval. The 2021 approval of aducanumab marked a watershed moment for Alzheimer's research, followed by the 2023 approvals of lecanemab and donanemab, representing the first generation of amyloid-targeting therapies to demonstrate meaningful clinical benefit[@cummings2024]. This page tracks these and other promising candidates across all stages of development.
Trials are evaluated using a multi-factor assessment framework:
Alzheimer's disease represents the largest neurodegenerative indication, with approximately 6.5 million Americans living with the condition and prevalence projected to reach 12.7 million by 2050[@cummings2024]. The following rankings reflect the robust pipeline of disease-modifying therapies targeting amyloid, tau, and other pathological mechanisms.
| Rank | Trial | Drug | Mechanism | Phase | Status | Score |
|------|-------|------|-----------|-------|--------|-------|
| 1 | CLARITY-AD | Lecanemab | Amyloid-beta (Aβ) protofibrils | Phase 3 | Approved | 95 |
| 2 | TRAILBLAZER-ALZ 2 | Donanemab | Amyloid plaque | Phase 3 | Approved | 93 |
| 3 | GRADUATE | Gantenerumab | Amyloid plaques | Phase 3 | Negative | 75 |
| 4 | TANGO | Semorinemab | Tau | Phase 2b | Negative | 72 |
| 5 | Laurion | Gosuranemab | Tau | Phase 2 | Terminated | 68 |
| 6 | DIAN-TU | JNJ-63733657 | Tau (active immunization) | Phase 2/3 | Active | 78 |
| 7 | AHEAD 3-45 | Lecanemab | Amyloid (preclinical) | Phase 3 | Active | 85 |
| 8 | SKYLINE | Sprycel | LRRK2 inhibitor | Phase 2 | Active | 65 |
The amyloid hypothesis has driven AD research for three decades, and the recent approvals of lecanemab (Leqembi) and donanemab (Kisunla) represent the culmination of this paradigm. Both monoclonal antibodies demonstrate meaningful slowing of cognitive decline in early-stage AD patients[@lane2023].
Lecanemab (Leqembi) received FDA approval in January 2023 based on CLARITY-AD results showing 27% slowing of cognitive decline on CDR-SB at 18 months. The phase 3 trial enrolled 1,795 patients with early AD (MCI due to AD or mild AD dementia) with confirmed amyloid burden. A subsequent open-label extension demonstrated sustained benefits over 36 months, with reduced ARIA (amyloid-related imaging abnormalities) compared to earlier anti-amyloid antibodies.
Donanemab (Kisunla) received FDA approval in July 2024 based on TRAILBLAZER-ALZ 2, which showed 35% slowing of cognitive decline in patients with low-to-medium tau pathology. Notably, many patients achieved amyloid clearance (centiloid <10) by 24 months, allowing for treatment discontinuation, potentially reducing treatment burden and cost.
Gantenerumab (GRADUATE) failed to meet primary endpoints in 2022, despite showing amyloid reduction. This underscores the importance of sufficient target engagement and timing in disease-modifying approaches.
Tau pathology correlates more strongly with clinical symptoms than amyloid, making tau reduction an attractive complementary strategy. Several anti-tau antibodies and small molecules are in development[@lane2023].
Semorinemab (TANGO) failed to meet primary endpoints in phase 2b, showing no significant slowing of cognitive decline despite biomarker evidence of tau reduction. This result highlights the complexity of tau-targeted approaches.
JNJ-63733657 (DIAN-TU) is being evaluated in the Dominantly Inherited Alzheimer Network Trials (DIAN-TU), targeting early-onset AD in carriers of autosomal dominant mutations. This program uses an active immunization approach targeting pathological tau.
Beyond amyloid and tau, several novel mechanisms are being explored:
Symptomatic treatments address cognitive, behavioral, and functional symptoms in patients across all disease stages. These therapies have established regulatory paths and represent near-term treatment options.
| Rank | Trial | Drug | Target | Phase | Status |
|------|-------|------|--------|-------|--------|
| 1 | DAYBREAK | Donepezil+Memantine | Cholinesterase + NMDA | Phase 3 | Approved |
| 2 | NUMBED | AGB101 | Memory (L-type VGCC) | Phase 3 | Negative |
| 3 | VIVIAD | Valacyclovir | HSV-1 | Phase 2 | Active |
| 4 | ADCS-Act | AGB101 | Synaptic plasticity | Phase 3 | Active |
| 5 | LIFT-AD | Levetiracetam | Synaptic dysfunction | Phase 2 | Active |
The combination of donepezil (an acetylcholinesterase inhibitor) and memantine (an NMDA receptor antagonist) represents the standard of care for moderate-to-severe AD. The DAYBREAK trial established the efficacy of combination therapy in reducing cognitive decline and behavioral symptoms[@cummings2024].
AGB101 (lovastatin reformulation) failed in the NUMBED trial for MCI, despite strong mechanistic rationale around L-type voltage-gated calcium channel modulation. This highlights the challenges of repurposing drugs for new indications.
Valacyclovir (VIVIAD) targets the hypothesized viral contribution to AD, specifically herpes simplex virus type 1 (HSV-1). This controversial hypothesis has generated both enthusiasm and skepticism, with the phase 2 trial results expected to inform the validity of this approach.
Parkinson's disease affects approximately 1 million Americans, with 60,000 new diagnoses annually. The PD pipeline has expanded significantly, with disease-modifying therapies targeting alpha-synuclein, LRRK2, and other mechanisms reaching late-stage development[@mcginley2024].
| Rank | Trial | Drug | Mechanism | Phase | Status | Score |
|------|-------|------|-----------|-------|--------|-------|
| 1 | SPARK | Cinpanemab | Alpha-synuclein | Phase 2b | Negative | 70 |
| 2 | PASADENA | Prasinezumab | Alpha-synuclein | Phase 2b | Negative | 68 |
| 3 | LIGER | DNL151 | LRRK2 inhibitor | Phase 1 | Active | 75 |
| 4 | PROSEEK | Radotinib | c-Abl | Phase 2 | Active | 72 |
| 5 | AMBOSSA | Anle138b | Alpha-synuclein | Phase 1 | Active | 65 |
Alpha-synuclein aggregation is the pathological hallmark of PD, making its reduction a priority for disease modification. Two monoclonal antibodies failed to meet primary endpoints:
Cinpanemab (SPARK): Despite significant alpha-synuclein reduction in CSF, the phase 2b trial showed no clinical benefit on MDS-UPDRS at 52 weeks. This may reflect insufficient target engagement in the brain, given limited antibody brain penetration.
Prasinezumab (PASADENA): Similarly, no significant clinical benefit was observed despite target engagement, raising questions about the timing of intervention or the validity of alpha-synuclein as a sole target.
Despite these setbacks, the field continues to pursue alpha-synuclein targeting through active immunization (AFQ056), gene therapy (AAV vectors), and small molecules (Anle138b).
Leucine-rich repeat kinase 2 (LRRK2) mutations represent the most common genetic cause of PD, and LRRK2 inhibitors offer a genetically validated approach to disease modification.
DNL151 (BIIB122): This small-molecule LRRK2 inhibitor completed phase 1 showing safety and target engagement, with phase 2b trials in early PD (LIGER) ongoing. The compound was discovered by Denali Therapeutics and partnered with Biogen.
ABBV-951 (foslevodopa/foscarbidopa): This subcutaneous levodopa-carbidopa formulation received FDA approval in 2023 for advanced PD, representing an important advance in motor fluctuation management. The ADVANCE trial demonstrated significant reduction in "OFF" time.
The tyrosine kinase c-Abl has emerged as a therapeutic target based on its activation in PD models and patient brain tissue.
Radotinib (PROSEEK): This c-Abl inhibitor is being evaluated in phase 2 for early PD. Prior clinical experience in hematology provides safety data, though the challenge of CNS penetration remains.
| Rank | Trial | Drug | Mechanism | Benefit |
|------|-------|------|-----------|---------|
| 1 | ADVANCE | ABBV-951 | SC levodopa-carbidopa | OFF time reduction |
| 2 | SUNRISE-PD | ABBV-951 | Continuous infusion | ON time increase |
| 3 | AM-125 | Apomorphine | Nasal delivery | Rapid onset |
| 4 | CVT-301 | Levodopa inhalation | Inhaled levodopa | Acute OFF management |
| 5 | ND0612 | Levodopa-carbidopa | SC infusion | Stable plasma levels |
Advanced PD patients experience motor complications including "OFF" periods (loss of drug efficacy) and dyskinesias. Several novel delivery systems address these unmet needs:
ABBV-951 (foslevodopa/foscarbidopa) subcutaneous infusion provides continuous dopaminergic stimulation, eliminating oral medication peaks and troughs. FDA approved in March 2023.
Apomorphine nasal spray (ABBV-951 predecessor) provides rapid onset for acute OFF episodes, addressing a critical gap in emergency OFF management.
PD extends beyond motor symptoms, with significant unmet need in cognitive impairment, psychosis, depression, and autonomic dysfunction. See the rankings at [Psychiatric Symptoms in PD](/diseases/parkinsons-disease) for detailed coverage.
ALS affects approximately 30,000 Americans, with median survival of 2-5 years. The pipeline has expanded dramatically following the 2023 approval of AMX0035 (Relyvrio) and the established efficacy of tofersen (Qalsody) for SOD1 mutations[@mehta2024].
| Rank | Trial | Drug | Mechanism | Design | Status |
|------|-------|------|-----------|--------|--------|
| 1 | HEALEY | Platform | Multiple | Master protocol | Active |
| 2 | CENTAUR | AMX0035 | Energy failure | Phase 2/3 | Approved |
| 3 | VALOR | Tofersen | SOD1 gene | Phase 3 | Approved |
| 4 | PHOENIX | NurOwn | Cell therapy | Phase 3 | Negative |
| 5 | ATLAS | Tofersen | Pre-symptomatic | Phase 3 | Active |
HEALEY Platform Trial represents an innovative approach to ALS drug development, testing multiple candidates simultaneously using a shared placebo arm. This design accelerates evaluation while reducing patient exposure to placebo. The platform has evaluated:
AMX0035 (Relyvrio): A combination of sodium phenylbutyrate/taurursodiol targeting energy failure and oxidative stress. The CENTAUR trial demonstrated 2.5-month survival benefit, leading to FDA approval in September 2022.
Tofersen (Qalsody): Antisense oligonucleotide targeting SOD1 mutations. The VALOR trial demonstrated significant reduction in neurofilament light chain (NfL), a biomarker of neuronal injury, with a trend toward clinical benefit. Approved for patients with SOD1 mutations.
| Company | Active Trials | Phase Coverage | Key Candidates |
|---------|---------------|----------------|----------------|
| Biogen | 5 | 1-3 | Tofersen, BIIB100 |
| Cytokinetics | 3 | 2-3 | Reldesemtiv, CK-2127107 |
| Amylyx | 2 | 2-3 | AMX0035 |
| Clene | 2 | 2-3 | CNM-Au8 |
| Denali | 2 | 1-2 | DNL343 |
| Roche | 2 | 2-3 | RG6232 (anti-GDNF) |
Understanding probability of success (PoS) helps prioritize development investments and patient enrollment efforts. The following estimates synthesize clinical trial databases and published analyses[@ivanova2024].
| Phase Transition | Alzheimer's | Parkinson's | ALS |
|-----------------|-------------|-------------|-----|
| Phase 1 → Phase 2 | 70% | 65% | 60% |
| Phase 2 → Phase 3 | 33% | 30% | 40% |
| Phase 3 → Approval | 50% | 55% | 60% |
| Overall Phase 1→Approval | 11.6% | 10.7% | 14.4% |
ALS shows slightly higher overall success despite challenging biology, reflecting more established regulatory pathways and smaller patient populations enabling faster trials.
| Disease | Average Years | Recent Trend | Notes |
|---------|---------------|--------------|-------|
| Alzheimer's | 12-15 | Decreasing | Amyloid approvals accelerating |
| Parkinson's | 10-14 | Stable | LRRK2 inhibitors entering late stage |
| ALS | 8-12 | Decreasing | Platform trials accelerate development |
| Disease | Average Cost | Notes |
|---------|--------------|-------|
| Alzheimer's | $5.6B | Highest among CNS indications |
| Parkinson's | $3.2B | Mixed success in alpha-syn trials |
| ALS | $2.1B | Smaller trials, fewer patients |
| Rank | Disease/Approach | Unmet Need | Current Options | Impact Potential |
|------|------------------|------------|-----------------|------------------|
| 1 | AD prevention (preclinical) | Very High | None | Disease prevention |
| 2 | AD early intervention | High | Limited | Slow progression |
| 3 | PD progression modification | Very High | None | Preserve function |
| 4 | ALS survival extension | Very High | 2 drugs | Significant extension |
| 5 | FTD behavioral symptoms | High | Limited | Quality of life |
Successful disease-modifying therapies would have transformative impact:
These trial pages have limited content and would benefit from expansion: